Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs
Nicola Colclough, Kan Chen, Peter Johnström, et al.
Clinical Cancer Research (2020) Vol. 27, Iss. 1, pp. 189-201
Open Access | Times Cited: 169

Showing 1-25 of 169 citing articles:

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
Alissa J. Cooper, Lecia V. Sequist, W. Marston Linehan
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 8, pp. 499-514
Open Access | Times Cited: 300
Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors
Xiaojing Du, Biwei Yang, Quanlin An, et al.
The Innovation (2021) Vol. 2, Iss. 2, pp. 100103-100103
Open Access | Times Cited: 114
Nanomedicine for brain cancer
Sabina Quader, Kazunori Kataoka, Horacio Cabral
Advanced Drug Delivery Reviews (2022) Vol. 182, pp. 114115-114115
Open Access | Times Cited: 99
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer
Pasi A. Jänne, David Planchard, Kunihiko Kobayashi, et al.
Journal of Clinical Oncology (2023) Vol. 42, Iss. 7, pp. 808-820
Open Access | Times Cited: 54
Oncogenic alterations in advanced NSCLC: a molecular super-highway
Alex Friedlaender, M. Pérol, Giuseppe Luigi Banna, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 36
Lazertinib: Breaking the mold of third-generation EGFR inhibitors
Kishan B. Patel, David E. Heppner
RSC Medicinal Chemistry (2025)
Open Access | Times Cited: 3
Free Drug Theory – No Longer Just a Hypothesis?
Scott Summerfield, James Yates, David Fairman
Pharmaceutical Research (2022) Vol. 39, Iss. 2, pp. 213-222
Closed Access | Times Cited: 59
Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials
Marco de Scordilli, Anna Michelotti, Elisa Bertoli, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 13, pp. 7222-7222
Open Access | Times Cited: 50
Targeting S100A9–ALDH1A1–Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer
Anup Biswas, Seo-Young Han, Yifan Tai, et al.
Cancer Discovery (2022) Vol. 12, Iss. 4, pp. 1002-1021
Open Access | Times Cited: 46
The Importance of the Pyrazole Scaffold in the Design of Protein Kinases Inhibitors as Targeted Anticancer Therapies
George Mihai Nițulescu, Gheorghe Stancov, Oana Cristina Șeremet, et al.
Molecules (2023) Vol. 28, Iss. 14, pp. 5359-5359
Open Access | Times Cited: 35
First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations
Yusuke Okuma, Kaoru Kubota, Mototsugu Shimokawa, et al.
JAMA Oncology (2023) Vol. 10, Iss. 1, pp. 43-43
Open Access | Times Cited: 34
Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study
Rolof G.P. Gijtenbeek, Ronald Damhuis, Anthonie J. van der Wekken, et al.
The Lancet Regional Health - Europe (2023) Vol. 27, pp. 100592-100592
Open Access | Times Cited: 33
EGFR is a potential dual molecular target for cancer and Alzheimer’s disease
Hee-Jeong Choi, Yoo Joo Jeong, Ji‐Eun Kim, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 32
Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer (BLOSSOM)
Sehhoon Park, Richard Baldry, Hyun Ae Jung, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 23, pp. 2747-2756
Open Access | Times Cited: 14
Osimertinib as Salvage Therapy in Advanced Non‐Small Cell Lung Cancer After Aumolertinib Resistance With T790M Mutation: A Case Report
Y. Tang, Jianfang Xu, Qingle Chen, et al.
Clinical Case Reports (2025) Vol. 13, Iss. 2
Open Access | Times Cited: 1
Mass spectrometry imaging in drug distribution and drug metabolism studies – Principles, applications and perspectives
Jonatan Riber Granborg, Anne Mette Handler, Christian Janfelt
TrAC Trends in Analytical Chemistry (2021) Vol. 146, pp. 116482-116482
Open Access | Times Cited: 44
A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903
Kentaro Ito, Masahiro Morise, Kazushige Wakuda, et al.
ESMO Open (2021) Vol. 6, Iss. 3, pp. 100115-100115
Open Access | Times Cited: 41
Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal Imaging
Nicole Strittmatter, Frances M. Richards, Alan Race, et al.
Analytical Chemistry (2022) Vol. 94, Iss. 3, pp. 1795-1803
Closed Access | Times Cited: 31
Blood–brain barrier penetration prediction enhanced by uncertainty estimation
Xiaochu Tong, Dingyan Wang, Xiaoyu Ding, et al.
Journal of Cheminformatics (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 29
Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer
Kelsey Pan, Kyle Concannon, Jing Li, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 10, pp. 716-732
Closed Access | Times Cited: 22
Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies
Sanjay Popat, Myung‐Ju Ahn, Simon Ekman, et al.
Targeted Oncology (2023) Vol. 18, Iss. 1, pp. 9-24
Closed Access | Times Cited: 20
Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC
Eun Ji Lee, Seung Yeon Oh, You Won Lee, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 8, pp. 1582-1594
Closed Access | Times Cited: 6
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Yvette N. Lamb
Targeted Oncology (2021) Vol. 16, Iss. 5, pp. 687-695
Open Access | Times Cited: 38
Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients
Christopher Alvarez‐Breckenridge, Jordi Remón, Yolanda Piña, et al.
American Society of Clinical Oncology Educational Book (2022), Iss. 42, pp. 147-165
Open Access | Times Cited: 26
Targeting Glioblastoma Stem Cells to Overcome Chemoresistance: An Overview of Current Therapeutic Strategies
Hyunkoo Kang, Haksoo Lee, Dahye Kim, et al.
Biomedicines (2022) Vol. 10, Iss. 6, pp. 1308-1308
Open Access | Times Cited: 26
Page 1 - Next Page

Scroll to top